Lumen Seeks Partner Take Its C. Diff Cocktail Into Phase III
With positive Phase II data for its oral biologic cocktail in curing and preventing recurrence of CDI, Lumen hopes to find a deep-pocketed partner to help fund a larger Phase III study.
Scrip - October 21, 2026

Roivant Plots Commercial Strategy As Lisraya Scores Big In NIU
As the CLARITY trials hit primary and key secondary endpoints, execs from Roivant subsidiary Priovant dug into how the non-infectious uveitis (NIU) treatment landscape has evolved.
Scrip - October 21, 2026

20% Clinical Adoption, 60% Life Sciences: Why Agilent Sees Upside In Proscia
Agilent’s $240m Proscia deal targets a digital pathology market split in two — clinical labs still largely on glass, biopharma already on screens — with companion diagnostics the clearest near-term opportunity for the acquired software.?
Medtech Insight - October 21, 2026

Can ADCs Plus PD-(L)1xVEGF Bispecifics Be A New Backbone In Cancer?
The big players have jockeyed into position through business development and are ramping up clinical trial programs with the goal of changing the standard of care in cancer.
Scrip - October 21, 2026

Intuitive Quantifies Instrument Pricing Cuts, Agrees To $450m Settlement As Q3 Revenue Rises 22%
Intuitive Surgical grew Q3 revenue 22% to $3.05bn at a 42% non-GAAP operating margin, but a newly quantified cut to da Vinci instrument pricing, a $450m class action settlement and 10% US procedure growth set the tone for the earnings call.
Medtech Insight - October 21, 2026

GSK’s Hibsago Will Transform Hep B Treatment But Leaves Room For Improvement
The newly approved Ionis-discovered therapy looks set to become a blockbuster by providing a functional cure to around 20% of eligible patients with hepatitis B.
Scrip - October 21, 2026

Pipeline Watch: AstraZeneca’s Breztri Aerosphere Wins US Approval in COPD and Asthma
Camurus’s Oclaiz is approved in Canada for acromegaly and Asahi Kasei’s Hovilpri is approved in the US for herpes simplex virus, while Nurix doses the first patient in the Phase III DAYBreak CLL-306 trial of bexobrutideg.
Scrip - October 21, 2026

The War Of Medicines: US Government To Loan $80m For Domestic Generics Manufacturing
The US Department of War has added direct lending to its artillery, committing to an $80m conditional loan to Antheia for generic drug key starting materials and active pharmaceutical ingredients onshoring.
Generics Bulletin - October 21, 2026

Brazilian Biosimilar Opportunity Opens As Samsung Bioepis Secures 10-Year Sole Supply For Eculizumab
Samsung Bioepis has secured a “landmark” 10-year deal to supply its eculizumab biosimilar rival to Soliris in Brazil, anchoring long-term growth in Latin America for the Korean giant.
Generics Bulletin - October 21, 2026

Somerset Pays Out $4m Over OTC Olopatadine Payments
Somerset Lifesciences has agreed with the US Department of Justice to pay $4m to settle allegations that it caused Medicare to wrongfully pay claims for its olopatadine generic for years by not changing its label to reflect a switch from prescription-only to OTC status.
Generics Bulletin - October 21, 2026

UK Recommends Indefinite CE-Marking For Devices In Great Britain
UK government confirms support for continued acceptance of CE-marked medical devices in Great Britain on a long-term basis.
Medtech Insight - October 21, 2026

AI Scientists Are On The Rise, But Can They Reach The Data They Need?
Sovereign AI and trusted research environments are quietly reshaping how pharma companies access and analyze data.
In Vivo - October 21, 2026

The FDA Says Aging Is On Its Agenda. Now It Wants The Data
At ARDD, senior FDA officials said aging will featurein the agency's next regulatory science priorities. However, no one at the FDA would say what an aging approval pathway looks like until developers bring evidence.
In Vivo - October 21, 2026

Little Support From Research On Women’s Health, Fitness On Extending Female Athletes’ Careers
Women’s sports organizations support their athletes’ health and fitness to extend their careers, but research is limited on women’s benefits from using vitamins, minerals and other nutrients.
HBW Insight - October 21, 2026

Athletes Bring Good Exposure For Supplement Brands, But Trust Means Convincing Consumers
At recent CRN conference, USANA chief scientific officer Kathryn Armstrong says the firm uses six-point check list to determine whether working with athletes will connect with consumers in its products, particularly women’s products.
HBW Insight - October 21, 2026

China’s New Cosmetics Safety Standard Puts Brands On Clock For 2027
As China’s new cosmetics safety standard starts a compliance clock for brands, cosmetic chemist Kelly Dobos explains in an exclusive Q&A what companies should be testing for now.
HBW Insight - October 21, 2026